Corvus Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $166.00K, a 564.00% increase year-over-year.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.34M, a 379.93% increase year-over-year.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $360.00K, a 620.00% increase year-over-year.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $25.00K.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $684.00K, a 905.88% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $68.00K, a 466.67% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $12.00K.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.22M, a 1280.68% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $166.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.34M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $684.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $360.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $25.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $279.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $68.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $50.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $12.00K 10-K · filed 2026-03-12 | |
| 2023-09-30 | $8.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $4.00K 10-Q · filed 2024-11-12 | |
| 2021-12-31 | $1.22M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $1.20M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $88.00K 10-K · filed 2023-03-28 | |
| 2020-09-30 | $64.00K 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $23.00K 10-Q · filed 2021-11-01 | |
| 2019-12-31 | $24.00K 10-K · filed 2022-03-10 | |
| 2019-09-30 | $16.00K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $5.00K 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $1.00K 10-Q · filed 2020-10-29 | |
| 2018-12-31 | $393.00K 10-K · filed 2021-03-25 | |
| 2018-09-30 | $159.00K 10-Q · filed 2019-10-29 | |
| 2018-06-30 | $41.00K 10-Q · filed 2019-10-29 | |
| 2018-03-31 | $7.00K 10-Q · filed 2019-10-29 | |
| 2017-12-31 | $731.00K 10-K · filed 2020-03-09 | |
| 2016-12-31 | $4.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |